Title : Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.

Pub. Date : 2015 Jan

PMID : 25322874






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. AZD 6244 KRAS proto-oncogene, GTPase Homo sapiens